Cure of Recurrent Ovarian Cancer: A Multicenter Retrospective Study
Approximately 10% of patients with recurrent ovarian cancer achieved a 4-year DFS and were mostly cured. The curing of cases not involving high-grade serous carcinoma (HGSC) was unrelated to the presence of pathogenic <i>BRCA</i> variants.
Authors
- Kazuto Nishio (ORCID: https://orcid.org/0000-0002-8275-0846)
- Kazuko Sakai (ORCID: https://orcid.org/0000-0003-1822-2720)
- Masayo Ukita
- Akihiko Ueda (ORCID: https://orcid.org/0000-0001-8139-9292)
- Yukio Yamanishi (ORCID: https://orcid.org/0009-0005-5010-9228)
- Kentaro Sekiyama (ORCID: https://orcid.org/0000-0002-3770-7099)
- Masaki Mandai (ORCID: https://orcid.org/0000-0003-4428-8029)
- Ikuko Emoto (ORCID: https://orcid.org/0000-0003-1427-2675)
- Motonori Matsubara
- Atsuko Taga
- Kaoru Abiko
- Masahiro Sumitomo (ORCID: https://orcid.org/0000-0003-1141-5618)
- Noriomi Matsumura (ORCID: https://orcid.org/0000-0002-4512-7975)
- Tomoyuki Otani (ORCID: https://orcid.org/0000-0002-4351-324X)
- Kosuke Murakami (ORCID: https://orcid.org/0000-0003-4278-5849)
- Minami Okudate
- Yasushi Kotani (ORCID: https://orcid.org/0000-0003-1364-1563)
Institutions
- Kanazawa University (JP)
- Kyoto University (JP)
- Tenri Hospital (JP)
- Kyoto Medical Center (JP)
- Kindai University Hospital (JP)
- Otsu Red Cross Hospital (JP)
- Shizuoka General Hospital (JP)
- Toyooka Hospital (JP)
- Japanese Red Cross Society Wakayama Medical Center (JP)
- Kitano Hospital (JP)
- Kobe City Medical Center General Hospital (JP)
- Kindai University (JP)
Publication Details
- Journal
- Cancers
- Published
- 2025-09-19
- DOI
- https://doi.org/10.3390/cancers17183069
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00